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Tumours of patients with node-positive rectal cancer were studied by immunohistochemistry for p53, BAX and vascular
endothelial growth factor expressions. Results were correlated to the relapse rate, the pattern of relapse and the event-free
survival after radical surgery and adjuvant chemoradiation. After a median follow-up of 60 months, 39 patients remained
disease-free and 40 patients relapsed (18 local relapses and 22 distant metastases). The majority of disease-free patients
showed p53 negative and vascular endothelial growth factor negative tumours. Local relapses occurred more frequently in
patients with p53 overexpressing tumours (P50.01), while distant metastases were in patients with vascular endothelial
growth factor positive tumours (P50.003). Patients with p53 negative or vascular endothelial growth factor negative tumours
showed better event-free survival than patients with p53 positive or vascular endothelial growth factor positive tumours. BAX
analysis did not show any association with patients’ outcome and it was unrelated to the p53 status. Adjuvant treatment
strategies for node-positive rectal cancer may be improved by identifying categories of high-risk patients. In this study, vascular
endothelial growth factor and p53 expressions correlated with recurrent disease, pattern of relapse and poor event-free
survival.
British Journal of Cancer (2002) 86, 744–749. DOI: 10.1038/sj/bjc/6600155 www.bjcancer.com
ã 2002 Cancer Research UK
Keywords: rectal cancer; apoptosis; angiogenesis; metastasis; chemotherapy; radiotherapy; p53; BAX; vascular endothelial growth
factor
Adjuvant chemoradiation represents the standard of care for
patients with resected stage II and III rectal cancer (Minsky,
1999). However, in spite of adjuvant therapies, a signiﬁcant
proportion of patients show local or distant recurrences with detri-
mental effect on quality of life and survival. The knowledge of
molecular features which determine the behaviour of individual
tumours may represent a fundamental step to identify high-risk
categories of patients and optimize therapeutic strategies (Vaughn
and Haller, 1997).
So far, the tumour-node-metastasis (TNM) staging system has
been considered the most important independent prognostic
feature in primary resected rectal cancer, however, it seems insufﬁ-
cient to identify subsets of prognostic categories. Recent
investigations have focused on innovative molecular markers which
may explain differences in the outcome of colorectal cancer
patients belonging to a homogenous TNM stage group (McLeod
and Murray, 1999).
Angiogenesis represents a key event in the process of tumour
invasion and metastasis (Folkman, 1996) and the vascular
endothelial growth factor (VEGF) is one of the most important
molecules promoting endothelial cell migration, proliferation
and differentiation (Grunstein et al, 1999; Arii et al, 1999). The
expression of this glycoprotein has been investigated in colorectal
carcinomas and its up-regulation has been related to the occur-
rence of relapses and the poor prognosis of primary resected
colorectal cancer (Takahashi et al, 1995; Ishigami et al, 1998;
Cascinu et al, 2000, 2001).
The ability of radiation and chemotherapy to eradicate tumour
cells and prevent relapses depends on successful induction of apop-
tosis in response to DNA damage. The ﬁne interplay between the
Bcl-2 family anti-apoptotic members and death-promoting
members like BAX and p53 ensures a regular apoptotic process,
while its disruption causes the loss of programmed cell death
(Reed, 1999).
The BAX protein plays a central role in regulating apoptosis
(Yin et al, 1997). It is located in the outer mitochondrial
membrane and its expression induces mitochondrial permeability
which leads to the release of cytochrome-c and a downstream
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www.bjcancer.comcascade of events promoting DNA degradation and cell death. In
experimental models, the p53 protein was found to be a positive
regulator of BAX transcription, also, the analysis of the p53/BAX
apoptotic pathway in colorectal carcinomas showed potential prog-
nostic value (Zhan et al, 1994; Miyashita and Reed, 1995; De
Angelis et al, 1998; Simms et al, 1998; Sturm et al, 1999).
These data prompted us to investigate markers of angiogenesis/
apoptosis in rectal carcinomas of patients with resected, node-posi-
tive disease. In their tumours, we evaluated the VEGF expression
and the p53/BAX apoptotic pathway; these molecular features were
related to the event-free survival, the relapse rate and the patterns
of recurrences after adjuvant chemoradiation.
MATERIALS AND METHODS
Human samples and clinicopathologic data
In this retrospective analysis, the study population consisted of
consecutive patients who underwent curative surgery for stage III
rectal cancer between 1994 and 1996. Inclusion criteria were: avail-
able archival tissue of the primary tumour, radical surgery with
negative resection margins and adequate follow-up information
(patients had to be observed for 5 years after surgery at least).
For the purpose of the analysis, patients had to be treated with a
homogeneous adjuvant protocol based on six chemotherapy cycles
with bolus ﬂuorouracil/folinic and pelvic radiation 45 Gy, with a
boost to a total of 54 Gy.
The follow-up consisted of interim history, physical examination,
haematologic studies, carcinoembryonic antigen levels and diagnostic
imaging (chest X-ray, abdominal ultrasonography) every 4 months in
the ﬁrst year, and every 6 months in the second through ﬁfth years.
Patients had barium enema or a colonoscopic examination 6 months
after surgery and subsequently every 12 months. Abdominal and
pelvic computed tomographic scan was performed for corroborative
evidence of relapse. The recurrences of rectal carcinoma had to be
proven by cytology biopsy or surgery.
The analysis was carried out on the primary tumour and all the
cases were reviewed by the pathologist. The selected blocks were
those in which mucosa, invasive edge and viable tumour were
present. The study was performed in a blind fashion, so that
patients’ outcome was unknown by the investigators performing
VEGF, p53 and BAX measurements.
BAX and p53 analyses
Formalin-ﬁxed, parafﬁn-embedded tumour blocks were analysed
immunohistochemically for BAX and p53 expressions using a stan-
dard avidin-biotin technique. Commercially available antibodies
which have been widely used for prognostic investigations in
colorectal cancer were chosen for the analysis (Baas et al, 1994;
McLeod and Murray, 1999; Sturm et al, 1999).
Sections (4 mm thick) were deparafﬁnized in xylene, rehydra-
tated in graded ethanol series and incubated in 3% hydrogen-
peroxide for 20 min. Specimens were placed in a plastic Coplin
jar with citric buffer and heated 462.5 min in a microwave
processor at 958C. Subsequently, sections were left in a Coplin
jar at room temperature for 30 min. Specimens were covered with
normal goat serum for 15 min to reduce nonspeciﬁc staining and
incubated at room temperature for 1 h with murine p53 monoclo-
nal antibody (DAKO DO7, Copenhagen, Denmark; dilution 1:75)
(Baas et al, 1994) and rabbit polyclonal antibody for BAX (Onco-
gene Research Products, Cambridge MA, USA; dilution 1:50)
(Sturm et al, 1999). Sections were washed with Tris-buffered saline
(TBS), incubated with 1:100 dilution of biotinylated goat anti-
mouse IgG at room temperature for 30 min, and covered with
1:100 dilution of streptavidin-biotin-peroxidase complex at room
temperature for 30 min. The antibody was localized with 3,3'-
diaminobenzidine tetrahydrochloride. Tissue sections were counter-
stained with light haematoxylin, dehydrated with ethanol and
mounted under a coverslip. Positive control sections were from a
colon carcinoma known to express high p53 and BAX proteins
levels. TBS, instead of the primary antibody was used as negative
control.
In each case, the entire section was examined on high-power
ﬁelds (6400) for BAX (cytoplasmic) and p53 (nuclear) immuno-
reactivity. The level of immunoreactivity was expressed as percen-
tage of stained cancer cells (0 to 100%). For the purpose of the
study and based on previous experiences (Sturm et al, 1999;
Schwander et al, 2000a), BAX and p53 expressions were classiﬁed
as negative (none or 410% of tumour cells stained) and positive
(410% of tumour cells stained).
VEGF analysis
Sections (4 mm thick) of the primary tumour tissue were deparaf-
ﬁned in xylene and rehydrated in a graded ethanol series.
Specimens were placed in a Coplin jar containing citric buffer
and heated 365 min in a microwave processor. Subsequently,
the sections were left in the Coplin jar at room temperature for
20 min. After an incubation in 3% hydrogen-peroxide for 8 min,
specimens were covered with normal swine serum for 10 min to
reduce nonspeciﬁc staining and incubated with a 1:20 dilution
of rabbit polyclonal antibody for VEGF (Biogenex, San Ramon,
CA, USA) at room temperature for 30 min. The sections were
washed and incubated with a 1:50 dilution of biotinylated swine
anti-rabbit IgG at room temperature for 20 min and then covered
with a 1:100 dilution of streptavidin-biotin-peroxidase complex at
room temperature for 20 min. The antibody was localized with
3,3'-diaminobenzidine tetrahydrochloride. Tissue sections were
counterstained with light haematoxylin, dehydrated with ethanol
and mounted under a coverslip. Normal rabbit IgG was substituted
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Table 1 Characteristics of the 79 patients included in the study
Age (years)
Median 65
Range 48–81
Sex
Male 44 (56%)
Female 35 (44%)
Tumour site
Upper rectum 24 (30%)
Middle rectum 24 (30%)
Lower rectum 31 (40%)
Grading
Well differentiated 20 (25%)
Moderately differentiated 30 (38%)
Poorly differentiated 29 (37%)
Tumour stage
pT2 6 (8%)
pT3 73 (92%)
Outcome
Disease free 39 (49%)
Local relapse 18 (23%)
Distant metastasis 22 (28%)
p53
Positive 36 (45%)
Negative 43 (55%)
VEGF
Positive 38 (48%)
Negative 41 (52%)
BAX
Positive 49 (62%)
Negative 30 (38%)
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(5), 744–749for primary antibody as the negative control. For positive controls,
normal mucosa known to express VEGF was stained for VEGF.
The staining results were evaluated independently by two inves-
tigators and each entire section was examined on high-power ﬁelds.
VEGF expression showed cytoplasmic localization and only clearly
immunoreactive cells were recorded positive. VEGF expression was
scored as percentage of immunoreactive cells and each case was
categorized as positive (410% of tumour cells stained) or negative
(none or 410% of tumour cells stained) (Cascinu et al, 2000,
2001).
Statistical analysis
Statistical analysis was performed to correlate the results of BAX,
p53, VEGF to the event-free survival and to the relapse rate after
adjuvant chemoradiation. Also, the pattern of relapse (local vs
distant metastases) was studied in relation to the expression of
the three markers. According to the cut-off values, the results of
BAX, p53 and VEGF analyses were used as dichotomized (catego-
rical) variable. Contingency tables were analysed by the Fisher’s
exact test or the Chi-square test as appropriate. The event-free
survival was calculated from the data of surgery to the time of
conﬁrmed relapse and the Kaplan–Meier method was adopted
to estimate survival curves. Differences between survival curves
were studied by means of the log-rank test. In addition, the
proportional hazards model (Cox, 1972) was used to assess the
prognostic importance of the three biomarkers for event-free survi-
val adjusting for relevant baseline clinico-pathologic features
(Moran et al, 1992; Stocchi et al, 2001). All the values were two-
sided and statistical signiﬁcance was deﬁned as P50.05.
RESULTS
Characteristics of patients
According to the inclusion criteria, tumours of 79 out of 87 conse-
cutive patients were analysed. Eight cases were excluded (9%); ﬁve
because of insufﬁcient follow-up information and four due to
unassessable archival tissue. In the 79 assessable patients, 39
patients remained disease-free, 18 patients had local relapse and
22 patients showed distant metastases. The distribution of clinico-
pathologic variables and the outcome after surgery and adjuvant
chemoradiation are reported in Table 1.
BAX and p53 analysis
Examples of immunohistochemical analysis for p53 and BAX
proteins expression are reported in Figure 1. High cytoplasmic
BAX protein levels were detected in 49 cases (62%) and low
expression in the remaining 30 cases (38%). The p53 protein was
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Figure 1 Examples of p53, BAX and VEGF immunohistochemical analyses in specimens of rectal carcinomas. Negative (A) and positive (B) p53 nuclear
immunoreactivity. Negative (C) and positive (D) cytoplasmic VEGF immunoreactivity. Negative (E) and positive (F) cytoplasmic BAX immunoreactivity.
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43 cases (55%). A preliminary combined analysis of BAX and p53
expressions did not show any association between the two markers
(data not shown).
The distribution of BAX positive and negative cases in disease-
free and relapsed patients did not show any signiﬁcant correlation
(Table 2). Also, differences between event-free survival curves of
patients with BAX positive and BAX negative tumours were not
statistically signiﬁcant. Patients whose tumours showed p53 overex-
pression had higher frequency of recurrences (Table 2) and worse
event-free survival (P50.01) than patients with with p53 negative
tumours (Figure 2A).
VEGF analysis
An example of immunohistochemical analysis for VEGF expression
is reported in Figure 1. VEGF positive and negative cases were 38
(48%) and 41 (52%) respectively. A signiﬁcantly higher proportion
of relapsed patients had VEGF positive tumours (26 out of 79
cases; 33%), while the majority of disease-free patients (27 out of
79 cases; 34%) showed VEGF negative tumours (Table 2). Patients
with VEGF positive tumours showed worse event-free survival
(P50.001) than patients with VEGF positive tumours (Figure 2B).
Local vs distant recurrences
The VEGF expression and the p53 status resulted in the two mole-
cular features which showed a signiﬁcant correlation with patients’
outcome. Accordingly, a further analysis of VEGF and p53 was
performed in tumours of the 18 patients with local recurrences
and the 22 patients with distant metastases (Table 3). A signiﬁcant
distribution of expression of both markers was found; the majority
of patients with distant metastasis had VEGF positive tumours, on
the other hand, local relapses occurred more frequently in patients
whose tumours showed p53 overexpression.
Multivariate analysis
Multivariate analysis with the COX proportional hazards model
showed that p53 and VEGF expressions were independent prognos-
tic factors for event-free survival (Table 4), whereas age, sex,
grading, tumour site, number of positive lymph nodes and BAX
expression were not independent indicators of prognosis.
DISCUSSION
In colorectal cancer, p53 mutations occur with a frequency of 35 to
60% (Hollstein et al, 1991). The most common are missense muta-
tions which usually prolong the half-life of the p53 abnormal
protein causing its nuclear accumulation and the detection by
immunohistochemistry. In rectal cancer, studies on the prognostic
role of p53 showed disappointing results; p53 overexpression or
gene mutation were found to have unfavourable inﬂuence on
survival (Adell et al, 1999; Liang et al, 1999; Schwadner et al,
2000a,b), but other studies did not conﬁrm the relationship
between the p53 status and patients’ outcome (Elsaleh et al,
1999; Nehls et al, 1999; Sturm et al, 1999).
A positive immunostaining for cytoplasmic BAX protein is an
indicator of its preserved pro-apoptotic function and high BAX
protein expression was found to possess positive prognostic value
in colorectal cancer (Ogura et al, 1999; Sturm et al, 1999).
Experimental data support a functional relationship between p53
and BAX, in fact, p53 is known to be a transcriptional regulator of
the BAX gene and the p53-to-BAX is considered as a major apop-
totic pathway (Zhan et al, 1994; Miyashita and Reed, 1995; Simms
et al, 1998). In vivo, mechanisms regulating the BAX/p53 apoptotic
pathway seem to be more complex and the relationship between
the p53 genotype/phenotype and BAX expression was not
conﬁrmed in colorectal carcinomas (De Angelis et al, 1998). In
advanced colorectal cancer, Sturm et al (1999) did not ﬁnd any
signiﬁcant association between BAX expression levels and the p53
status. Schwandner et al (2000b) investigated the prognostic value
of the apoptotic index compared to molecular features of rectal
carcinomas and they found that apoptosis did not possess a prog-
nostic role, whereas p53 was an independent predictor for both
recurrence and survival.
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Table 2 Analysis of BAX, p53 and VEGF expressions in the 39 disease-
free patients and the 40 relapsed patients
Disease free Relapsed
BAX positive 25 (32%) 24 (30%)
P=0.8
BAX negative 14 (18%) 16 (20%)
p53 positive 12 (15%) 24 (30%)
P=0.01
p53 negative 27 (34%) 16 (21%)
VEGF positive 12 (15%) 26 (33%)
P=0.003
VEGF negative 27 (34%) 14 (18%)
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Figure 2 (A) Event-free survival analysis in the 36 patients with p53
overexpressing tumours and the 43 patients with p53 negative tumours.
(B) Event-free survival analysis in the 38 patients with VEGF positive tu-
mours and the 41 patients with VEGF negative tumours.
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(5), 744–749A key point for the interpretation of p53 and BAX results are
the molecular modiﬁcations in response to chemoradiation (Rosen
et al, 1999). Apoptosis increases after treatment with 5-ﬂuorouracil
or radiotherapy and it is correlated with enhanced BAX expression
(Sugamura et al, 1997; Ohno et al, 1998; Kokawa et al, 1999). In
rectal cancer a signiﬁcantly higher expression of BAX was observed
after preoperative chemoradiation (Tannapfel et al, 1998) and in
cervical cancer increased BAX expression after radiotherapy was
related to better tumour control (Harima et al, 2000). These data
suggest that raising of BAX expression rather than its basal level
may correlate with apoptosis. Accordingly, it is possible that a
‘dynamic’ study of BAX with pre- and post-treatment determina-
tions could clarify interactions with the p53 status and its
prognostic role.
In the present study, BAX and p53 expressions did not show any
association and only p53 overexpression correlated with local fail-
ure after surgery and adjuvant chemoradiation. The predictive
value of p53 is supported by experimental data which showed
functional relationships between wild-type p53 and radiosensitivity
(Rosen et al, 1999). In rectal cancer, p53 expression was found to
be predictive of response to preoperative chemoradiation (Spitz et
al, 1997; Fu et al, 1998; Luna-Perez et al, 1998) and the p53 status
correlated with the frequency of local recurrences (Sato et al, 1998;
Adell et al, 1999). Our results seem to conﬁrm the potential predic-
tive role of p53, however, this ﬁnding requires further
investigation, including a combined analysis with a surgery-alone
group.
VEGF up-regulation has been linked to prognosis in colorectal
cancer (Takahashi et al, 1995; Ishigami et al, 1998; Cascinu et al,
2000, 2001). In our study, VEGF expression was associated with
tumour recurrence and poor event-free survival, also, patients
whose tumours were VEGF positive had signiﬁcantly higher
frequency of distant metastases. These data support the role of
an angiogenic phenotype in the progression of rectal cancer and
the metastatic pattern of individual tumours. Neovascularization
sustained by VEGF up-regulation is necessary for tumour nourish-
ment and it is a potential route for haematogenous spread and
metastasis. Previous data contribute to support this hypothesis;
high VEGF protein expression or mRNA levels correlated with
the M1 stage and liver metastases from colorectal carcinomas
(Kang et al, 1997; Tokunaga et al, 1998; Lee et al, 2000).
The results of the present study have strengths and limitations.
To the best of our knowledge it is the ﬁrst report of a concomitant
analysis for p53, BAX and VEGF expressions in rectal cancer. The
analysis has been performed in a homogenous population of
patients with node-positive disease whose rates of local and distant
metastases are comparable to that of other series (Minsky, 1999).
Patients received the same protocol of adjuvant chemoradiation
and they underwent ﬁxed follow-up controls. Possible biases could
derive from the retrospective nature of the study and the immuno-
histochemical analysis for p53 which may not always discriminate
between wild-type and mutated gene. In colorectal tumours, the
5% p53-positive nuclei was experimentally determined as a relevant
cut-off level to assess TP53 gene damage (Clausen et al, 1998).
However, according to previous prognostic studies in rectal cancer
(Sturm et al, 1999; Schwander et al, 2000a), we set the cut-off value
for p53 at 10% positive stained cells. Finally, pre- and post-treat-
ment determinations of BAX could have supplied more
information, however, this dynamic analysis was unfeasible in
patients who had received postoperative chemoradiation.
In the present study, p53 overexpression and VEGF up-regula-
tion showed a prognostic role and they inﬂuenced event-free
survival of patients with surgically-resected node-positive rectal
cancer. This ﬁnding, together with the distinct pattern of relapse
associated with p53 overexpression (local recurrences) or VEGF
up-regulation (distant metastases) may contribute to identify
categories of high-risk patients and tailor speciﬁc treatment stra-
tegies. More speciﬁc and aggressive radiotherapy programs may
be delivered to patients with increased risk for local relapses,
whereas patients at risk for distant metastases may beneﬁt from
more potent combination chemotherapy regimens or new anti-
angio-genetic molecules. Our results deserve further investigation,
since new prognostic molecular markers may represent a funda-
mental step to improve the post-surgical management of rectal
cancer.
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